Navigation Links
Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
Date:4/21/2008

COMPANY WILL INITIATE COMMERCIAL LAUNCH PROGRAM TO ADD NEW CENTERS AND TO

INCREASE AWARENESS AMONG CARDIOLOGISTS

PLEASANTON, Calif., April 21 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has received FDA approval of its PMA (PreMarket Approval) application, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) as a bridge-to-transplantation (BTT) in patients suffering from advanced-stage heart failure.

The approval follows a successful clinical trial involving more than 450 BTT patients, including those enrolled under Continued Access Protocols, and a unanimous recommendation for approval from the FDA Circulatory System Devices Advisory Panel last November.

"The HeartMate II is the first continuous flow device to receive FDA approval for this intended use in the U.S., representing a milestone in the treatment of advanced-stage heart failure patients and for the clinicians who treat them," said Gary F. Burbach, president and chief executive officer of Thoratec. "As our clinical trial indicated, the HeartMate II represents a new era in the treatment of advanced-stage heart failure with data demonstrating excellent survival rates, quality of life and functional capacity for a broad range of patients. This patient experience has created a high level of enthusiasm for the HeartMate II within the clinical community. We are hopeful that the device's trial experience, ease of implantation, small size and ability to provide longer duration support will result in broader adoption of mechanical circulatory support for the treatment of thes
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
3. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
4. InterMune Announces Progress on Pirfenidone in IPF
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:9/1/2014)... (PRWEB) September 01, 2014 "Women struggle ... These hormonal daily changes begin as early as 15, ... their lives negotiating the ups and downs of hormone ... thin or even healthy sizes seems to rage against ... As a woman in her 40's begin to face ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... The Outlier Series announced the next short e-Book ... one of the exceptional women featured in the series’ ... . The title of the upcoming mini e-Book is ... . McClendon is currently a full-time physician’s assistant, and ... WeTV show, Raising Sextuplets. , Jenny was chosen as ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as ... can have devastating effects on those who develop it. ... they are not produced by electrical anomalies in the ... estimated that the numbers of persons suffering PNES may ... , Dr. Lorna Myers, Director of the Northeast ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... CINCINNATI, July 28 LCA-Vision Inc. (Nasdaq: LCAV ... Lasik Plus ((R)) brand, today announced financial and operating results for ... , Second Quarter 2009 Operational and Financial Results ... , Revenue was $31.7 million compared with ...
... , , , MINNEAPOLIS, July ... and marketer of state-of-the-art cardiac surgery products, announced today that it ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , ... Focus on Healthcare Conference at the Millennium Broadway Hotel in New ...
... , GLEN ROCK, N.J., July 28 ... of Fingertip Formulary Accounts((R)), a state-of-the art web-based platform ... data and resources at an account level. The ... now provides immediate, real-time integrated provider-level data that includes ...
... , , DENVER, ... caregiver workflow in healthcare environments, today announced that Alegent ... ThinIdentity solution throughout its healthcare system. The first installation ... Iowa. A 278-bed facility, Mercy Hospital has over 1,000 ...
... July 28 According to a new market,research report, ,Drug-Device ... the total drug-device,combination market is expected to be worth US$18.54 ... for nearly 30.9% of the total revenues.,The global market is ... 2014. , Browse 144 market data ...
... ... first analog frame grabber for the National Instruments CompactRIO embedded real-time platform at the ... NIWeek the world,s leading graphical system design conference and exhibition hosted by National Instruments. ... Irvine, CA ...
Cached Medicine News:Health News:LCA-Vision Reports Second Quarter Financial Results 2Health News:LCA-Vision Reports Second Quarter Financial Results 3Health News:LCA-Vision Reports Second Quarter Financial Results 4Health News:LCA-Vision Reports Second Quarter Financial Results 5Health News:LCA-Vision Reports Second Quarter Financial Results 6Health News:LCA-Vision Reports Second Quarter Financial Results 7Health News:LCA-Vision Reports Second Quarter Financial Results 8Health News:LCA-Vision Reports Second Quarter Financial Results 9Health News:LCA-Vision Reports Second Quarter Financial Results 10Health News:LCA-Vision Reports Second Quarter Financial Results 11Health News:LCA-Vision Reports Second Quarter Financial Results 12Health News:LCA-Vision Reports Second Quarter Financial Results 13Health News:LCA-Vision Reports Second Quarter Financial Results 14Health News:ATS Medical to Participate at Upcoming Investor Conferences 2Health News:Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... (DHEA-S) is the sulfate ester of DHEA, ... conversion of DHEA in adrenal and extradrenal ... secreted by the adrenal cortex, and is ... DHEA possesses relatively weak androgenic activity, which ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: